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Abstract
Hepatitis C virus (HCV) infection is a worldwide public health burden and it is estimated that 185 million people are
or have previously been infected worldwide. There is no effective vaccine for prevention of HCV infection; however,
a number of drugs are available for the treatment of infection. The availability of direct-acting antivirals (DAAs) has
dramatically improved therapeutic options for HCV genotype 1. However, the high costs and potential for
development of resistance presented by existing treatment demonstrate the need for the development of more
efficient new antivirals, or combination of therapies that target different stages of the viral lifecycle. Over the past
decades, there has been substantial study of compounds extracted from plants that have activity against a range of
microorganisms that cause human diseases. An extensive variety of natural compounds has demonstrated antiviral
action worldwide, including anti-HCV activity. In this context, plant-derived compounds can provide an alternative
approach to new antivirals. In this review, we aim to summarize the most promising plant-derived compounds
described to have antiviral activity against HCV.
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Background
Hepatitis C virus (HCV) infection is a worldwide public
health burden and it is estimated that 185 million people
are or have previously been infected worldwide, repre-
senting almost 3% of the global population. Most infec-
tions persist and chronically infected individuals have a
high risk to develop liver cirrhosis and hepatocellular
carcinoma after 10 to 30 years of infection [1–3].
HCV transmission occurs by parenteral via. The main
route of transmission was blood transfusion until in the
1990s when Food and Drug Administration (FDA) au-
thorized medical centers to screen blood for HCV. Now-
adays, the sharing of contaminated syringes by drug
users and inadequate sterilization of medical equipment
are the main transmission routes [4–6].
There is no effective vaccine for prevention of HCV
infection, however, a number of drugs are available for
the treatment of infection. Until recently, the standard
therapy was based on pegylated interferon (IFN) plus ri-
bavirin (RBV), resulting in a sustained virological re-
sponse in approximately 50% of patients infected with
HCV genotypes 1a/1b and 80% of those infected with
genotypes 2 or 3 [7–9]. The availability of new, direct-
acting antivirals (DAAs) targeting the NS3/4A protease,
NS5B polymerase and NS5A protein have dramatically
improved therapeutic options for HCV genotype 1 [10,
11]. However, the high costs and potential for develop-
ment of resistance presented by existing treatment dem-
onstrate the need for the development of more efficient
new antivirals, or combination of therapies that target
different stages of the viral lifecycle. The efforts to de-
velop innovative anti-HCV drugs are challenged by the
viral high mutation rate, which allows the rapid emer-
gence of resistant strains to DAAs directed to the NS5A
and NS3 regions. Further issues to overcome include the
development of a drug which can impair the virus with
limited side effects on the host cell and the affordable
access to care in developing countries.
Over the past decades, there has been substantial
study of compounds extracted from plants that have ac-
tivity against a range of microorganisms that cause
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human diseases. Natural compounds have received in-
creasing attention for their therapeutic potential, includ-
ing antiviral properties [12, 13]. An extensive variety of
natural compounds has demonstrated either antiviral ac-
tion worldwide, including anti-HCV activity [2, 12–14],
or hepatoprotective effect as described for naringenin,
(−)-epigallocatechin-3-gallate (EGCG), silymarin and
caffeine [15–18].
In this context, plant-derived compounds can provide
an alternative approach to new antivirals. Natural com-
pounds present characteristics such as high chemical
diversity, lower cost of production and milder or inexis-
tent side effects than conventional treatment [19]. Add-
itionally, most of the drugs used today in the clinic were
first discovered from plants and microorganisms [20–22].
In this review, we aim to summarize the most promising
plant-derived compounds described to have antiviral activ-
ity against HCV.
The HCV replication cycle
HCV is a small, enveloped virus, grouped within the genus
Hepacivirus of the Flaviviridae family [23]. Its single-
strand positive genomic RNA of 9600 kb in length has a
single open reading frame, with untranslated regions
(UTR) in both 5′ and 3′ ends. These UTR regions are well
conserved RNA structures essential for the translation of
viral proteins and viral genome replication [24, 25].
The HCV viral particles are associated with low density
lipoproteins (LDL) and very low-density lipoproteins
(VLDL) and this association is related to infectivity.
Virions circulate in the blood-stream of patients as lipovir-
oparticles [26–28]. The first stage of HCV infection is the
attachment of virus particles on the surface of the host cell
followed by the specific interaction of the viral envelope
glycoproteins E1 and E2 with cellular receptor molecules,
such as the tetraspanin CD81, scavenger receptor class B
type 1 (SRB1), and the tight junction components claudin
1 (CLDN1) and occludin (OCLN) [29]. HCV entry into
the host cells by clathrin-mediated endocytosis [30]. The
viral RNA is released into the cytoplasm after the uncoat-
ing of the nucleocapsid and is translated at the rough
endoplasmic reticulum (ER) under the control of the viral
internal ribosome entry site (IRES) giving rise to a single
polyprotein which is co- and posttranslationally cleaved
into 10 proteins: the structural proteins core and envelope
glycoproteins E1 and E2, the viroporin p7 and the non-
sctructural proteins NS2, NS3, NS4A, NS4B, NS5A and
NS5B [31, 32]. To process HCV structural proteins a
minimum of two cellular peptidases are required, while
the non-structural proteins are cleaved by viral peptidases
[33]. The non-structural viral proteins NS3/4A, NS4B,
NS5A and NS5B assemble and interact with host proteins
to form the virus replication complexes that will amplify
viral RNA via the prior synthesis of negative strand
intermediates. HCV replication occurs in the host cell
cytoplasm in a specialized membranous compartment
from the endoplasmic reticulum, termed the membranous
web. To form this compartment, viral proteins induce a
rearrangement of the ER membranes [34–36]. Host pro-
teins as cyclophilin A, VLDL/LDL pathways and mRNA-
122 seem to be associated with the improvement of HCV
replication cycle [28, 37]. The assembly of new viral parti-
cles occurs in close vicinity to lipid droplets and the core
protein interacts with NS5A to recruit nascent genomes.
Apolipoprotein E also seems to be essential to the forma-
tion of lipoviroparticles [27, 38–41] and modifications
observed in E1 and E2 proteins of virions indicate that
these proteins are processed by Golgi complex [42].
Plant-derived compounds with anti-hcv properties
Blockade of HCV entry
Viral entry is an attractive point of intervention to pre-
vent virion access into non-infected cells. This multistep
process can be inhibited by small molecules, including
compounds extracted from natural sources that have
shown to abrogate HCV infectivity. Unlike for example
HIV, no entry inhibitor has been licensed for the treat-
ment of HCV infected patients. Efficient inhibition of
this stage of virus life cycle can play an important role in
a future combined therapy which could include com-
pounds with different targets and modes of action.
The blockade of HCV entry by the proteins griffithsin
(GRFT) and scytovirin (SVN) originally isolated from red
[43] and blue-green algae [44], respectively, was reported
by Takebe et al. [45]. By their unique structural characteris-
tics, these proteins are able to bind to multiple carbohy-
drate moieties [46–48] and demonstrated to inhibit HCV
in both cell culture and pseudoparticle assays by targeting
HCV envelope glycoproteins E1 and E2. The authors first
observed an effect of these proteins using a replicon assay
system and a potent activity against HCV in a cell-based
assay with JFH-1 virus (SVN EC50 17 nM, GRFT EC50
0.4 nM; CC50 = 34 mM and a selectivity index (SI) of
84,000). The results were expanded upon utilizing chi-
meras encompassing the E1 and E2 proteins from the
HCV 2a isolate J6 or the HCV 1b isolate TH, showing that
multiple viral isolates were sensitive to both GRFT and
SVN. Further, by using HCV pseudoparticle assay bearing
E1 and E2 proteins from the HCV 2a isolate J6 and the
HCV 1b isolate TH, they demonstrated that GRFT (EC50’s
ranging from 0.3–14.1 nM) and SVN (EC50’s ranging from
3.2–96 nM) acted early in the viral lifecycle, inhibiting all
three HCV isolates. They were able to demonstrate that
these proteins activity on HCV entry was explained by
their targeting of high-mannose oligosaccharides on either
E1 or E2, but did not inhibit binding of E2 to CD81. In
addition, they showed that GRFT was active in an
albumin-urokinase plasminogen activator/severe combined
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immunodeficient chimeric mouse model of HCV infection
with up to a 2.5-log reduction of viral titers. The authors
also tested GRFT in vivo by using a transgenic mouse
model. The dose of 20 mg/kg/day of GRFT was adminis-
tered for a total of 18 days and at the end of the experi-
ment a reduction of ~ 2.7 log in HCV levels was observed
in serum.
Recently, a study which evaluated the anti-HCV proper-
ties of Limonium sinense extracts demonstrated that an
aqueous extract from the underground part of the plant
(LS-UW) potently inhibited HCV early entry events by
impairing virus attachment and entry/fusion without affect-
ing viral replication, translation and cell-to-cell propagation
[49]. They evaluated the bioactive molecules in LS-UW that
could contribute to its anti-HCV effect and identified gallic
acid (GA) as the compound which most inhibited HCVcc
infection (EC50 = 24.31 ± 6.90 μM; CC50 = 346.59 ±
27.44 μM; SI = 14.25). GA also targeted early viral entry,
specifically inactivating cell-free virions and blocking virus
binding to the host cell surface, with little effect against the
post-binding viral entry/fusion, showing that further com-
pounds may be acting on this stage. Additionally, interac-
tion(s) between constituents could result in synergistic
effects to exert anti-HCV efficacy observed by treatment
with LS-UW. The authors demonstrated that both LS-UW
and GA could also suppress HCV infection of primary
human hepatocytes. However, the specific mechanisms by
which LS-UW and GA act was not clarified.
The inhibition of early steps of HCV life cycle was also
observed by the treatment of HuH 7.5 cells infected with
Gaussia luciferase reporter viruses (Jc1-GLuc) with a
saponin-rich methanolic extract of Bupleurum kaoi roots
(BK) or its associated saikosaponins SSa, SSb2, SSc, and
SSd [50]. Bupleurum spp. roots (Radix Bupleuri) are
frequently used as herbal treatments for liver diseases and
saikosaponins showed to attenuate liver fibrosis [51]. By
adding compounds at different times to the infectious
HCV culture system Lin et al. demonstrated that SSb2 at
50 μM was able to block infection by neutralizing free virus
particles and abolishing viral attachment and entry/fusion.
In contrast, BK (50 μM) and SSa (8 μM) appeared to be
most effective during the entry/fusion event [50]. The
molecular mechanism of action of SSb2 is related to the
antiviral effect of this compound on HCV glycoproteins
during the initial stages of infection. The pan-genotypic
antiviral activity was also demonstrated using chimeric
HCV particles from genotypes 2b (J8/JFH1), 3a (S52/
JFH1), and 7a (QC69/JFH1), and clinical HCV isolates of
different genotypes. These data provide evidence that SSb2
may act as an efficient inhibitor of HCV viral entry in vitro.
Haid et al. screened a library of natural phenolic com-
pounds isolated from extracts of Marrubium peregrinum
L (Lamiaceae) for their anti-HCV activity [52]. By using
the highly permissive human hepatoma cell line Huh7-
Lunet/CD81 with firefly luciferase reporter viruses based
on the intragenotypic genotype 2a chimera Jc1, they iden-
tified an active extract. Ladanein was the dominant flavon-
oid and demonstrated to possess the antiviral activity by
treatment of cells with natural or synthesized compound
(BJ486K) that was based on the natural chemical struc-
ture. Natural ladanein and BJ486K inhibited a post-
attachment entry step, but not RNA replication or assem-
bly. BJ486K, similar to CD81-specific antibody used as
one of the HCV entry control inhibitors, was active not
only during HCV inoculation but also after virus binding,
it was shown to be effective against all major HCV geno-
types (1a, 1b, 2b, 3a, 4a, 5a, and 6a) with an EC50
≤4.2 μM, including a variant (mutation G451R within the
HCV envelope protein E2) [53] that is resistant to the
entry inhibitor ITX5061 by reducing viral dependency on
SR-BI-receptor [54], indicating that it inhibits HCV cell
entry independently of viral genotype/subtype. The anti-
viral activity of BJ486k was also demonstrated in primary
human hepatocytes in a dose dependent manner with an
EC50 of approximately 10 μmol/L. Additionally, combined
administration of BJ486K and cyclosporine A showed a
synergistic effect in inhibition of HCV infection. The oral
bioavailability of BJ486K was stablished in mice, with
plasma level of 329 nmol/L after a single oral dose of
0.25 mg/kg. However, the effects of BJ486K against HCV
in vivo have not been tested [52].
Delphinidin, a polyphenol plant pigment that gives a
blue-purple color to flowers and berries, was reported as an
entry inhibitor against all HCV genotypes [55]. Delphinidin
exhibited strong inhibition of infection (EC50 of 3.7 ±
0.8 μM), The effects of delphinidin were evaluated by add-
ing the compound to the cells prior to, during and after in-
fection. However, the antiviral activity was only observed
during infection, suggesting an activity of delphinidin on
the virus particle. The results of a binding assay demon-
strated that delphinidin reduced HCV attachment by de-
creasing the amount of HCV RNA bound to the cell
surface. However, delphinidin had no effect on virus aggre-
gation or disrupted the envelope of virus particle. The au-
thors also investigated whether delphinidin affected the
morphology of virus particle by incubating HCVpp (geno-
type 2a) with delphinidin or controls and cryoTEM ana-
lysis. They demonstrated that this polyphenol acts on E1
and E2 glycoproteins inducing conformational changes on
the viral particles, affecting interaction between the viral
particles and cell surface.
Interference with HCV replication
Inhibiting HCV replication by blocking the synthesis of
newly viral genomes is a promising strategy for the de-
velopment of new antivirals. Targeting this step of HCV
life cycle specifically abrogates the production of viral
genomes in HCV infected cells.
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The inhibition of HCV replication by plant-derived com-
pounds was previously described. In 2014, Choi et al. re-
ported that xanthone compounds identified within ethanol
extract from mangosteen frit peels (MG-EtOH) suppressed
HCV replication [56]. Garcinia mangostana L., commonly
known as Mangosteen, belongs to the Clusiaceae family
and is cultivated manly in Indonesia, Malaysia, Philippines
and Thailand. MG-EtOH was able to block HCV genome
replication by reducing both protein and RNA levels in in-
fectious replicon systems of genotypes 1b (EC50 5.1 μg/mL)
and 2a (EC50 3.8 μg/mL). An additive effect of MG-EtOH
and the NS5A inhibitor daclatasvir [57] was also confirmed
[56]. It was also shown that MG-EtOH had a modest in-
hibitory effect on NS5B in vitro and was able to restore the
increasing levels of reactive oxygen stress (ROS) production
by HCV infection to normal levels. α- and β-mangostins
(EC50 6.3 μg/mL and 2.7 μg/mL) were known to be the
molecules responsible for inhibitory effect on HCV.
The reduction of protein and RNA levels was also
shown by the treatment of subgenomic replicon harbour-
ing cells with 3-hydroxy caruilignan C (3-HCL-C) isolated
from Swietenia macrophylla stems, from the Meliaceae
family, used as a folk medicine in Malaysia. 3-HCL-C ex-
hibited high anti-HCV activity at nontoxic concentrations,
with an EC50 value of 10.5 ± 1.2 μM. Additionally, combi-
nations of 3-HCL-C and interferon-α (IFN-α), HCV NS5B
polymerase inhibitor (2′-C-methylcytidine; NM-107) or
an HCV NS3/4A protease inhibitor (Telaprevir; VX-950)
increased the suppression of HCV RNA replication. The
mechanism by which 3-HCL-C interfered with HCV repli-
cation was shown to involve induction of IFN-stimulated
response element transcription and IFN-dependent anti-
viral gene expression [58].
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is
mainly found in roots of Plumbago indica L., a plant of
the Plumbaginaceae family. Plumbagin has demonstrated
several biological activities including anticancer [59], anti-
inflammatory and antimicrobial [60]. Hassan et al. re-
ported a dose-dependent effect of plumbagin on HCV life-
cycle by the infection of Huh-7.5 cells with the full-length
HCV FL-J6/JFH/JC1 for 6 h and treatment with plumba-
gin for 96 h. The intracellular HCV RNA was quantified
by real-time PCR and plumbagin demonstrated an IC50
value of 0.57 μM/L and SI = 53.7 [61]. The authors ana-
lyzed the expression of non-structural protein NS3 of
HCV and the cellular protein hA3G, a cytidine deaminase
that was described as a host factor with anti-HCV activity
[62]. Results demonstrated that plumbagin increased the
expression of hA3G protein and decreased NS3 protein
expression in a dose-dependent manner.
Xanthohumol (XN) is the main prenylated chalcone
present in hops (Humulus L., Cannabaceae) [63, 64]. This
natural product has been shown to possess biological prop-
erties including anticancer [65], anti-inflammatory [66, 67]
and antiviral activities [68–70]. Lou et al. demonstrated that
XN at 7.05 or 14.11 μM achieved an inhibitory effect on
HCV replication in vitro similar to that of IFN- α 2b by
measuring luciferase activity and RNA levels in Huh7.5
cells infected with J6-JFH1 isolate of HCV [71]. The mode
of action of XN on HCV infection remains to be elucidated.
However, author suggested that XN may act as a host-
targeting inhibitor by affecting the triglyceride-synthesizing
enzyme diacyglycerol acyltransferase-1 (DGAT1) expres-
sion or/and the microsomal triglyceride transfer protein
(MTP) activity, based on previous evidence [72–74]. Yang
and coworkers administrated 10 mg/ml of XN in Tupaia
belangeri infected with HCV. The XN was divided into 3
doses and given to the animals by gavage three times a day
for 12 weeks. The results demonstrated a decrease in liver
damage and modulates oxidative reaction and apoptosis in
animals treated with XN [75].
The flavonoid Apigenin, which is present in many fruits
and vegetables, also has diverse biological effects, includ-
ing improvement of the cancer cell response to chemo-
therapy [76], tumorigenesis [77, 78], modulating immune
cell function [79], and anti-platelet activity [80]. Apigenin
is also demonstrated to have inhibitory effect on the mat-
uration of a subset of miRNAs and on the subsequent
miRNA functions [81]. MicroRNA122 (miR122), abun-
dantly expressed in the liver and essential for the HCV
RNA stability and propagation, positively regulates HCV
replication through binding to the 5’-UTR of the HCV
genome [82, 83]. In 2014, Shibata et al. demonstrated that
5 μM of Apigenin inhibited HCV replication in vitro with-
out affecting cell growth or viability. The inhibitory effect
of apigenin on HCV replication was possibly explained by
decreasing the levels of mature miR122 through the inhib-
ition of the phosphorylation of TRBP, a component of
miRNA-generating complexes via impaired mitogen-
activated protein kinase activation [84].
Coffee intake has been associated with lower rates of
liver disease progression in chronically HCV infected pa-
tients [85]. Several compounds extracted from coffee, in-
cluding caffeine, may have beneficial effects on the liver
[86–88]. Caffeine has been demonstrated to have an an-
tiproliferative effect on liver cancer cells [89], may limit
liver fibrosis [90] and interact with cellular pathways to
slow the progression of liver diseases [91]. The effects of
caffeine on HCV replication was evaluated in 2015 by
Batista et al. by using a cell line stably harbouring the
SGR-Feo JFH-1 and by infecting Huh-7.5 cells with J6/
JFH1 HCV isolate [92]. Caffeine efficiently inhibited
HCV replication in a dose dependent manner and redu-
cing HCV RNA levels and protein expression by up to
80% of the non-treated control at the highest safely tol-
erated concentration (2 mM). The half-maximal inhibi-
tory concentration (IC50) was reported to be in order of
0.726 mM. The authors demonstrated that cell cycle
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progression pattern and apoptosis levels remained un-
changed in caffeine treated cells. Induction of autophagy
was also investigated but no significant difference was
found apart from a higher proportion of cells in an au-
tophagic state observed in the presence of caffeine.
Compounds extracted from Brazilian plants also showed
to dramatically inhibit HCV replication in vitro. The com-
pounds APS (EC50 = 2.3 μM), a natural alkaloid isolated
from Maytrenus ilicifolia, the tetrahydrofuran lignans 3*43
(EC50 = 4.0 μM) and 3*20 (EC50 = 8.2 μM) and the seco-
lignan 5*362 (EC50 = 38.9 μM) from Peperomia blanda
were tested by their inhibitory effects on HCV replication
using either subgenomic reporter SGR-Feo-JFH1 and the
full-length Rluc-J6/JFH1. Data demonstrated that by treat-
ment with these compounds dramatically reduced HCV
RNA and protein levels and acted mainly by preventing the
formation of new replication complexes [93]. It was also
shown that replication blockade by Brazilian naturally oc-
curring compounds was independent of HCV genotype
and was not affected by variants described to confer resist-
ance to the NS5A targeting compound daclatasvir [57, 94,
95]. At the same work, a natural kavalactone F8*40 isolated
from Piper fuligineum, showed a significant but not dra-
matic effect on IRES-directed translation, correlated with a
reduction of protein levels in the presence of this com-
pound, suggesting that its mode of action is related to the
inhibition of IRES-mediated translation [93].
The effect on baseline IRES translation was earlier
showed by treating of cells with quercetin, a plant-derived
flavonoid present in fruits, vegetables, leaves and grains
[96]. The inhibition of HCV replication by quercetin was
first demonstrated by Gonzalez et al. in 2009 [97]. These
researchers sought to identify interaction between HCV
NS5A and cellular protein that could play a role in the
virus production. By co-immunoprecipitation and co-
localization assays they detected interactions between
NS5A and the heat shock proteins (HSP) HSP40 and
HSP70. Using a transient transfection luciferase-based tis-
sue culture system, the authors demonstrated that treat-
ment with quercetin, an inhibitor of HSP synthesis,
markedly reduced HCV IRES activity and its increase by
NS5A. However, quercetin was found to decrease IRES ac-
tivity either in absence or in presence of NS5A. Quercetin
treatment (50 μM) did not reduce viral genome copy
numbers but NS5A protein levels and had strongly inhib-
ited HCV production in cell culture. RNA replication of
SGR -harboring cells was not affected by treatment, sup-
porting that the major role of HSP40 and HSP70 may not
be in genome replication but rather in subsequent stages
in the viral life cycle. Additionally, the effects of quercetin
could be related to a global reduction in most of the HSP
family members, not restricted to the HSP40 and HSP70,
as siRNA-mediated depletion of HSP proteins had no
effect on HCV particle production.
Later in 2012, the same research group further investi-
gated the mode of action of quercetin and other structurally
related bioflavonoids [98]. Using a HCV IRES bicistronic
reporter assay system, they showed that the translation in-
hibitory effect of quercetin treatment was NS5A dependent,
consistent with the mechanism of NS5A/HSP7 complex-
driven IRES-mediated translation of viral proteins. They
also demonstrated that quercetin had a lesser effect on
intracellular infectious virus assembly and had no effect on
virion secretion. Furthermore, quercetin had a strong in-
hibitory effect on HSP70 expression, supporting the conclu-
sion that bioflavonoids mediate their antiviral effects at
least in part by blocking HSP expression and underscore
the role of HSPs in HCV life cycle.
Also in 2012, Bachmetov et al. identified quercetin as
the active substance responsible for the inhibition of
NS3 protease activity by Embelia ribes plant extracts
[99]. They showed that it was found to inhibit NS3
activity in a specific dose-dependent manner in an in vitro
catalysis assay. Using a model system in which NS3 engi-
neered substrates were introduced into NS3-expressing
cells, they demonstrated that quercetin-mediated inhib-
ition could be explained by an NS3 protease specific
mechanism. This inhibition of NS3 was confirmed in cell
culture with NS3 protease-dependent fluorescent reporter
systems. They also demonstrated that quercetin at
10 μg/mL inhibited HCV RNA replication up to 70% as
analysed in the SGR system, as well as the HCV infec-
tious virus production by treating cells infected with
intergenotype HJ3–5 chimeric virus up to 95%. Taking
all data available, these authors suggested that the high
inhibition efficiency of virus production could be attrib-
uted to a mutual inhibitory effect of quercetin targeting
both NS3 protease and NS5A.
In addition to these described inhibitory mechanism,
Pisonero-Vaquero et al. investigated in 2014 the contribu-
tion of oxidative/nitrosative stress (ROS/SNS) and lipid me-
tabolism modulation in the inhibition of HCV replication
by quercetin [100]. They showed that quercetin inhibited
HCV replication in Huh7 cells expressing full-length geno-
type 1b HCV replicon in a dose-dependent manner alone
(up to 61%, 5 μM), or combined with IFNα (up to 72%,
5 μM), and HCV NS5A and core protein expression was
also reduced (up to 78%, 5 μM). Quercetin acted by de-
creasing HCV-induced ROS/RNS generation (up to 35%,
5 μM) and lipoperoxidation (up to 30%, 5 μM) in replicat-
ing cells. The treatment significantly decreased HCV-
induced intracellular lipid accumulation in a dose-
dependent manner (Q5: 55% vs HCV-G1 vehicle-treated
cells), inhibited liver X receptor (LXR)a-induced lipid accu-
mulation in LXRa-overexpressing and replicon-containing
Huh7 cells (Q5: 34% vs HCV-G1 vehicle-treated cells). In-
activation of phosphatidylinositol 3-kinase (PI3K)/AKT
pathway was inferred to be the mechanism involved in
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modulating LXRa-dependent lipogenesis by quercetin and
may contribute to the inhibition of viral replication.
An additional anti-HCV activity by quercetin-based
treatment was recently suggested [101]. Lulu et al. pre-
dicted the 3D structure HCV NS2 protein and performed
docking studies to identify phytochemical compounds
which could have strong affinity towards its protease. Ten
plants-derived compounds were tested and quercetin
revealed minimum binding energy of 7.95 kcal/mol with
NS2, demonstrating the theoretical potential of this com-
pounds to target HCV NS2 protease.
The inhibitor activity of NS3/4A protease was also
shown by testing triterpenes from Cynomorium songari-
cium [102]. “SuoYang” (Cynomorium songaricum Rupr;
Cynomoriaceae) is a parasitic plant, which grows mainly
in the northern part of China, such as Inner Mongolia
Autonomous Region and Gan Su Province. Using an
HCV protease assay it was shown that malonyl ursolic
acid hemiester tested triterpen was the most potent
inhibitor of NS3/4A in this free-cells method.
Assembly and release
Naringenin is a dietary supplement derived from narin-
gin, one of the most abundant flavonoids in citrus fruits.
It has been demonstrated to possess anti-oxidant, anti-
inflammatory, anti-carcinogenic properties, and also to
reduce cholesterol levels both in vitro and in vivo
[103–107]. Grapefruit’s bitter taste is caused by the pres-
ence of naringin, which is metabolized into naringenin. It
was previously demonstrated that Naringenin, or its glyco-
sylated form, can reduce cholesterol levels in animals and
in human cells both in vivo and in vitro [108, 109].
In 2008, Nahmias et al. demonstrated a dose-dependent in-
hibitory effect of naringenin on HCV release [74]. The au-
thors treated infected Huh-7.5.1 cell with naringenin for
24 h, supernatant was collected, cells were harvested and
HCV RNA was measured by qRT-PCR. The results showed
a decrease of HCV core secretion and extracellular HCV
positive strand RNA, demonstrating that naringenin at the
concentration of 200 μM could inhibit up to 80% HCVsecre-
tion. Later, Goldwasser et al. related that naringenin was able
to block the assembly of intracellular HCV particles [110].
The authors suggested that the mode of action of naringenin
could be the PPARα activation. PPARα is a transcription fac-
tor associated with lipid metabolism in the liver, related to
the reduction of lipogenesis and VLDL secretion [111], and
these mechanisms are extremely related to HCV infectivity
due to affect the viral assembly. By treating Huh7.5.1 cells in-
fected with JFH1 virus with 200 μM naringenin or 10 μM of
a classical PPARα agonist (WY14643), they were able to
demonstrate that naringenin or WY14643 caused an inhib-
ition of HCV RNA secretion and did not affect the intracellu-
lar levels of HCV RNA. Naringenin was also co-incubated
with WY14643 and no increased effect was observed,
demonstrating the possible effect of naringenin in PPARα ac-
tivation. More recently, Lulu et al. analysed by molecular
docking studies the structural interactions between narin-
genin and the protein NS2 protease [101]. They demon-
strated that naringenin exhibited a lower minimum binding
energy (− 7.97 kcal/mol) than RBV (− 5.89 kcal/mol) to bind
to NS2 protein, suggesting that naringenin requests a lesser
amount of energy to disrupt HCV NS2 protein. These results
demonstrated a theoretical potential of naringenin as an in-
hibitor of HCV NS2 protease [112]. However, this data has
not been confirmed by in vitro or in vivo assays yet.
Broad spectrum activity against HCV
Honokiol, a lignan isolated from leaves of Magnolia officiais,
was shown to have multiple effects on HCV infection,
strongly inhibiting HCV infection (EC50 1.2 μM) in both the
J6/JFH1 reporter virus system (p7-Rluc2A) and in a pseudo-
particles system containing glycoprotein of three different
HCV genotypes (1a, 1b and 2a) [100–102]. The mechanism
in which honokiol affects HCV entry was reported by Lan
et al. [113]. The treatment of cells with this natural com-
pound suppressed the OCLN and SR-BI receptors involved
in HCV infection. The authors also demonstrated that
honokiol was able to inhibit HCV IRES-mediated transla-
tion. However, this antiviral action was observed only at the
highest concentration treatment (30 μM) and no effect was
detected at concentration lower than 20 μM. Honokiol was
also effective against HCV replication as observed against
two SGR, the genotype 1b (pFK-I389luc-NS3–3′/5.1) and
genotype 2a (pSGR-Fluc-JFH1).
Oxymatrine and matrine are the two major alkaloids in
the aqueous extract from the Sophora root. Oxymatrine is
reported to have antiviral activity against HCV in cell cul-
tures and has shown hepatoprotective activity in an animal
study [114–116]. In a clinical perspective, the components
oxymatrine and matrine found in Sophora roots have
shown to reduce viral load and liver fibrosis [19, 117]. Mao
et al. evaluated the efficacy and safety of oxymatrine for the
treatment of hepatic fibrosis in patients with chronic viral
hepatitis B or C. Patients took three doses of 300 mg oxy-
matrine a day for 52 weeks. The data obtained demon-
strated a decrease of alanine aminotransferase (ALT) and
histological inflammatory activity decreased from 46.08 (±
3.84) to 4.00 (± 2.97) after treatment with oximatrine based
on Semi-quantitative scoring system [118].
Epigallocatechin-3-gallate is the major component in
green tea. This polyphenol belongs to the Flavonoid family
and is reported with antiviral activity against a range of vi-
ruses such as Chikungunya virus [119], Enterovirus-71
[120] and HCV [55, 121] in addition to other activities as
anti-inflammatory and antioxidative [122] anti-cancer
[123]. EGCG was initially described by Ciesek et al. as an
inhibitor of HCV entry and cell to cell spread. The inhib-
ition of HCV entry was confirmed by incubating EGCG
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Table 1 Plant-derived antivirals tested in cellular models with activity against HCV life cycle. Structures from PubChem (https://
pubchem.ncbi.nlm.nih.gov)
Compound Structure Extracted from Viral Inhibition
step
HCV
genotypes
EC50 CC50 Reference
Griffithsin
a
Griffithsia sp Entry 1b, 2a 0.4 nM 33.6 μM [45]
Scytovirin
a
Scytonema varium Entry 1b, 2a 17 nM 23.8 μM [45]
Gallic Acid Limonium sinense Entry 2a 24.31 ± 6.90 μM 346.59 ± 27.43 μM
Saikosaponin b2 Bupleurum kao Entry 2b, 3a,7a 16.13 ± 2.41 μM 740.4 ± 28.35 μM
Ladanein Marrubium
peregrinum L
Entry 1a, 1b, 2b,
3a, 4a, 5a, 6a
≤2.54 μmol/L 98.04 μmol/L [52]
Delphinidin Anthocyanidin Entry 1a, 2a 3.7 ± 0.8 μM – [55]
Epigallocatechin-3-gallate Camellia sinensis Entry/
Replication
1a, 2a
2a
1b,2a
10.6 ± 2.9 μM
2.5 μg/mL
17.9 μM
232.6 μM [121]
[125]
[123]
Xanthone extract – Garcinia
mangostana L.
Replication 1b
2a
5.1 μg/mL
3.8 μg/mL
12.8 μg/mL [56]
3-hydroxy caruilignan C Swietenia
macrophylla
Replication 1b 10.5 ± 1.2 μM – [58]
Plumbagin Plumbago indica L. Replication 2a 0.57 μM 30.65 ± 1.25 μM/L [61]
Xanthohumol Humulus L. Replication 2a – – [71]
Apigenin Flavone Replication 2a – – [84]
Caffeine
-
Alkaloid Replication 2a 0.726 mM – [92]
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Table 1 Plant-derived antivirals tested in cellular models with activity against HCV life cycle. Structures from PubChem (https://
pubchem.ncbi.nlm.nih.gov) (Continued)
Compound Structure Extracted from Viral Inhibition
step
HCV
genotypes
EC50 CC50 Reference
APS
b
Maytrenus ilicifolia Replication 2a 2.3 μM 135.24 μM [93]
3*43
b
4.0 μM 18.8 μM
3*20
b
8.2 μM 32.8 μM
5*362
b
Peperomia bland Replication 2a 38.9 μM 73.91 μM
Quercetin Embelia ribes Replication 1a, 2a
1b
– – [99]
[100]
Ursolic acid Cynomorium
songaricium
Replication - 16 μg/mL – [102]
Acetyl ursolic acid 11 μg/mL –
Malonyl ursolic
acid hemi- ester
8 μg/mL –
Glutaryl ursolic
acid hemiester
3 μg/mL –
Oxalyl ursolic
acid hemiester
5 μg/mL –
Succinyl ursolic
acid hemiester
10 μg/mL –
Ursolic acid
methyl ester
94 μg/mL –
Naringenin Flavanone Release/
Assembly
2a -
109 μM
– [74]
[110]
Honokiol Magnolia
officiais
Entry/
Replication
1a,1b, 2a 1.2 μM 35 μM [113]
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with infected Huh-7.5 in a dose-dependent manner. The
results demonstrated the efficient blockage of virus entry
with an approximate IC50 of 2.5 μg/mL. To demonstrate
whether EGCG can inhibit cell to cell spread the authors
infected Huh-7.5 with HCVcc in the presence of EGCG
and then co-cultured the infected cells with näive Huh-7.5
cells in an agarose overlay assay [124]. EGCG was added to
the co-culture and no spread was observed during the
treatment with EGCG at 3 μg/mL [125]. Calland et al. de-
scribed EGCG acting on the early steps of virus entry by
disrupting lipid metabolism in the host cells [121]. Recently,
the same authors described that EGCG blocks virus infec-
tion (EC50 of 10.6 ± 2.9 μM) due to its action on E1 and E2
glycoproteins and induces conformational changes in the
viral particles, a mechanism which affects the interaction
between the viral particles and cell surface, as observed for
delphinidin [55].
Chen et al. performed in vitro assays using the cell cul-
ture derivative JFH-1 HCV (HCVcc) system with GFP
[126] and demonstrated that EGCG strongly decreased
HCV infection (EC50 of 17.9 μM) in a mechanism related
to the virus entry inhibition. However, this group also ob-
served a moderate action of EGCG on HCV replication.
The authors used an HCV construct with an in-frame de-
letion in the HCV E1E2-coding sequence [127], to avoid
reinfection. Huh-7.5.1 cells were treated with 80 μM
EGCG 4 h post transfection and the HCV RNA levels
were measured 72 h later. The results showed that EGCG
blocked HCV replication by the reduction of both the
HCV RNA levels (66%) and the expression of viral pro-
teins NS3 and NS5A. The same inhibitory effect was also
observed for HCV genotype 1b (Con-1 replicon) [128] (re-
duction of 56,6% of HCV RNA and a decrease of NS3 and
NS5) [123]. Taken together this studies demonstrated the
extraordinary potential of EGCG against HCV.
Silymarin is a mixture of silybin A, silybin B, isosilybin
A, isosilybin B, silychristin, isosilychristin, and silydianin
extracted from Silybum marianum (milk thistle). This
extract has shown recently to block virus entry, RNA
and protein expression, virus production and cell to cell
spread of virus [129]. Additionally, this compound dem-
onstrated a hepatoprotective effect on treated cells [130].
One of the major components of silymarin is silibinin, a
mixture of semi-purified silybin A and silybin B and
commercially available.
In 2007, Polyak et al., showed that silymarin was capable
of blocking HCV infection using JFH1 [131] and also
H77/JFH and J6/JFH systems [129]. The authors demon-
strated that silymarin effect could be due to the inhibition
of NS5B polymerase activity, although it did not seem to
be the main mechanism of action of this compound.
Blaising et al. tested the purified compounds from sily-
marin extract silybin A, isosilybin A, silybin B, isosilybin
B, silibinin, silychristin, taxifolin, isosilychristin and sily-
dianin. The authors evaluated the antiviral activity of these
compounds on HCV infection and demonstrated that sili-
binin is the main inhibitor of HCV fusion in silymarin ex-
tract. Using live-cell imaging studies in 3D–confocal
microscopy, the authors observed the HCV intracellular
trafficking into the host cells and demonstrated that silibi-
nin blocked endosomal traffic in Huh-7.5. HCV entry in
host cells is a complex processes which involves the pres-
ence of receptors CD81, OCLN, CLDN1 and SRB1 [29]. It
is also associated with clathrin receptor that is related to
clathrin-mediated endocytosis [30, 132]. Silibinin also
inhibited HCV entry in primary human hepatocytes by
hindering clathrin-mediated endocytosis and consequently
viral entry [133].
Future perspectives
Most of the plant derived compounds cited in this review
showed promising results in in vitro analysis (Table 1).
However, some of the challenges in this field are the lack of
in vivo studies, bioavailability and pharmacokinetics of
plant derived compounds against HCV. In addition, some
natural compounds were reported as Pan Assay INterfer-
ence compoundS (PAINS), which may affect the results
obtained by bioassays [134]. Compounds which possess
these characteristics, such as quercetin and EGCG, need to
be analyzed very carefully. Additionally, further analysis to
confirm the effect of the compounds in vivo should be per-
formed and also tests for obtaining the bioavailability and
pharmacokinetics. According to the literature, the bioavail-
ability of natural compounds is very diverse. The
Table 1 Plant-derived antivirals tested in cellular models with activity against HCV life cycle. Structures from PubChem (https://
pubchem.ncbi.nlm.nih.gov) (Continued)
Compound Structure Extracted from Viral Inhibition
step
HCV
genotypes
EC50 CC50 Reference
Silymarin Extract – Silybum marianum Entry/
Replication
2a
1a/2a
1b, 3a
-
5 μM
15 ± 4 μM
-
-
[131]
[129]
[133]
Silibinin Silybum marianum Entry 1b, 3a 34 ± 3 μM – [133]
aStructures from RCSB Protein Data Bank (http://www.rcsb.org)
bStructures from [93]
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compounds Ladanein, after a single oral dose of 0.25 mg/
kg, demonstrated a bioavailability of 329 nmol/L [52]. A
pharmacokinetics study for XN demonstrated that the
maximum XN concentrations were 45 ± 7 μg/L, 67 ±
11 μg/L, and 133 ± 23 μg/L for 20, 60, and 180 mg oral
dose, respectively [135]. Alternatives to improve the bio-
availability of some natural compounds have been de-
scribed with the advancement of nanotechnology [136], by
improving the delivery of these compounds to their targets
and raising the half-life of the compound within the body.
However, there are only few studies on this topic by now.
Conclusion
In recent years, the standards treatments against hepatitis
C have shown several improvements. However, many issues
remain unsolved, as the prevalence of resistance associated
variants to DAAs. Natural products represent an increasing
source in development of new drugs and could either im-
prove the DAAs treatment or provide alternative ap-
proaches in the HCV treatment. Several plant-derived
compounds have shown effectiveness against HCV and the
improvement on the HCV assay systems allows a better
evaluation of the antiviral activity of compounds act on
HCV life cycle. However, many mechanisms of action of
active compounds remain unknown. Considering the
current worldwide biodiversity there may be many plant-
derived products to be discovered by their antiviral actions.
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